{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:39:27Z","timestamp":1759333167050},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,7,17]],"date-time":"2006-07-17T00:00:00Z","timestamp":1153094400000},"content-version":"vor","delay-in-days":5121,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[1992,7,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polyethylene glycol\u2010modified recombinant human interleukin\u20102 (PEG\u2010IL\u20102) represents a cytokine with prolonged circulatory half\u2010life and increased antitumor activity as compared to recombinant interleukin\u20102 (rIL\u20102) after systemic administration. We studied whether PEG\u2010IL\u20102 would also be advantageous in locoregional immunotherapy using a syngeneic tumor model. Intradermal inoculation of line\u201010 tumor cells into the flanks of strain\u20102 guinea\u2010pigs results in a fast\u2010growing tumor and regional lymph\u2010node metastases. Treatment schedules were started on day 7 after inoculation in animals with established tumors. First, groups of 5\u20106 animals were treated with repeated intratumoral and perilymphatic rIL\u20102 or PEG\u2010IL\u20102 injections. PEG\u2010IL\u20102 caused significant growth inhibition of both the primary tumor and the regional lymph\u2010node metastases at lower doses and with less frequent administration than rIL\u20102. The best schedule for PEG\u2010IL\u20102 was 3 injections a week for 5 weeks, resulting in cure of 4\/17 and 5\/5 (\u03c1 &lt; 0.01) animals at the 2 most efficient dose levels tested. Subsequent experiments indicated that the intratumoral and not the perilymphatic injection route was essential for the obtained antitumor effect. Furthermore, 12\/12 animals cured after PEG\u2010IL\u20102 treatment rejected a rechallenge with line\u201010 tumor cells, whereas no cures were seen after rIL\u20102 injections. PEG\u2010IL\u20102 therefore appears to be a valuable substance for intratumoral immunotherapy. <jats:italic>\u00a9 1992 Wifey\u2010Liss, Inc.<\/jats:italic><\/jats:p>","DOI":"10.1002\/ijc.2910510524","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T22:56:10Z","timestamp":1171925770000},"page":"812-817","source":"Crossref","is-referenced-by-count":30,"title":["Polyethylene\u2010glycol\u2010modified interleukin\u20102 is superior to interleukin\u20102 in locoregional immunotherapy of established guinea\u2010pig tumors"],"prefix":"10.1002","volume":"51","author":[{"given":"Vera","family":"Mattijssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianne T. M.","family":"Balemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Steerenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter H. M.","family":"de Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,17]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)93039-R"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-2478(87)90162-3"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-2478(90)90074-Z"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910470424"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19881215)62:12<2482::AID-CNCR2820621205>3.0.CO;2-9"},{"key":"e_1_2_1_7_1","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4049\/jimmunol.134.2.1305","article-title":"Lymphokine\u2010activated tumor inhibition in vivo. The local administration of interleukin\u20102 triggers non\u2010reactive lymphocytes from tumor\u2010bearing mice to inhibit tumor growth","volume":"134","author":"Forni G.","year":"1985","journal-title":"J. Immunol."},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.4049\/jimmunol.138.11.4033","article-title":"Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity","volume":"138","author":"Forni G.","year":"1987","journal-title":"J. Immunol."},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/291335a0"},{"key":"e_1_2_1_10_1","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1016\/S0021-9258(18)68146-3","article-title":"Relationship of etfective molecular size to systemic clearance in rats of recombinant interleukin\u20102 chemically modified with water\u2010soluble polymers","volume":"263","author":"Knauf M. J.","year":"1988","journal-title":"J biol. Chem."},{"key":"e_1_2_1_11_1","first-page":"2009","article-title":"Pharmacokinetics of recombinant interleukin\u20102 in humans","volume":"50","author":"Konrad M. W.","year":"1990","journal-title":"Cancer Res."},{"key":"e_1_2_1_12_1","first-page":"4420","article-title":"Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T\u2010cell growth factor","volume":"41","author":"Lotze M. T.","year":"1981","journal-title":"Cancer Res."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/325262a0"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199102000-00009"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.2.319"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.33"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.181845"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910340312"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704093161501"},{"key":"e_1_2_1_20_1","first-page":"153","article-title":"New clinical trials with interleukin\u20102: rationale for regional administration","volume":"8","author":"Roth A. D.","year":"1989","journal-title":"Nat. Immun. Cell Growth Regul."},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01669425"},{"key":"e_1_2_1_22_1","first-page":"81","article-title":"A pilot study of intralymphatic interleukin\u20102. II. Clinical and biological effects","volume":"9","author":"Sarna G.","year":"1990","journal-title":"J. biol. Resp. Mod."},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01754205"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.10.1618"},{"key":"e_1_2_1_25_1","first-page":"2193","article-title":"Local interleukin 2 therapy of mouse mammary tumors of various immunogenicities","volume":"48","author":"Vaage J.","year":"1988","journal-title":"Cancer Res."},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910470417"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.160.5.1450"},{"key":"e_1_2_1_28_1","first-page":"119","article-title":"Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living mycobacterium bovis","volume":"49","author":"Zbar B.","year":"1972","journal-title":"J. nat. Cancer Inst."},{"key":"e_1_2_1_29_1","first-page":"821","article-title":"Transplantable hepatomas induced in strain 2 guinea pigs by diethylnitrosamine: characterization by histology, growth and chromosomes","volume":"43","author":"Zbar B.","year":"1969","journal-title":"J. nat. Cancer Inst."},{"key":"e_1_2_1_30_1","first-page":"6521","article-title":"Schedule dependency of the antitumor activity and toxicity of polyethylene glycol\u2010modified interleukin 2 in murine tumor models","volume":"49","author":"Zimmerman R. J.","year":"1989","journal-title":"Cancer Res."},{"key":"e_1_2_1_31_1","first-page":"5667","article-title":"Induction of lymphokine\u2010activated killer cells in strain 2 guinea pigs with human interleukin\u20102","volume":"46","author":"Zwilling B. S.","year":"1986","journal-title":"Cancer Res."}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.2910510524","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.2910510524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T13:56:03Z","timestamp":1698069363000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.2910510524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,7,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1992,7,9]]}},"alternative-id":["10.1002\/ijc.2910510524"],"URL":"https:\/\/doi.org\/10.1002\/ijc.2910510524","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,7,9]]}}}